Silo Pharma has recently completed an extensive study on SPC-15, an innovative intranasal treatment for PTSD. The study focused on determining the optimal dosage and pharmacokinetics of the drug, with promising results. All animal subjects tolerated the highest dose well, showing rapid absorption and sustained exposure over 24 hours. These findings suggest that a once-daily intranasal dosing schedule could be ideal for humans.
SPC-15, a groundbreaking serotonin 4 (5-HT4) receptor agonist, has the potential to treat PTSD, anxiety, and other stress-related disorders. If successful in clinical trials, SPC-15 may qualify for expedited FDA approval through the 505(b)(2) pathway. Silo Pharma is actively collaborating with Columbia University on further research into SPC-15.
In addition to SPC-15, Silo Pharma is working on various other programs, including SP-26 for fibromyalgia and chronic pain, SPC-14 for Alzheimer’s, and SPU-16 for multiple sclerosis. The company is on track to submit a pre-IND application to the FDA by the end of the second quarter, a significant step forward in advancing SPC-15 towards potential clinical use.
SILO Stock Sees Slight Decline on February 28, 2024: What Investors Need to Know
On February 28, 2024, SILO stock experienced a slight decline in its performance. The stock closed at $1.55, a decrease of $0.04 from the previous market close, representing a 2.52% drop in the price of SILO shares. SILO is currently trading in the middle of its 52-week range and below its 200-day simple moving average, indicating a lack of significant upward momentum and possible challenges in price movement. Despite the drop in price during regular trading hours, SILO stock remained unchanged in after-hours trading, suggesting no significant movement in the stock price after the market closed. Overall, the performance of SILO stock on February 28, 2024, was relatively flat with a slight decline in price. Investors should monitor any potential developments that could impact the stock’s performance in the future.
SILO Stock Performance Review: Revenue Flat, Net Income Decreases, EPS Declines
On February 28, 2024, SILO stock had a mixed performance based on the financial data provided by CNN Money. The total revenue for the company was reported at $72.10K for the past year, which remained flat compared to the previous year. Similarly, the total revenue for the third quarter of the year was $18.02K, also showing no growth compared to the previous quarter.
The net income for SILO stock showed a significant decrease over the past year. The net income was reported at -$3.91M for the past year, representing a decrease of 200.16% compared to the previous year. On a positive note, the net income for the third quarter of the year improved to -$660.16K, showing an increase of 34.83% compared to the previous quarter.
The earnings per share (EPS) for SILO stock also showed a decline over the past year. The EPS was reported at -$1.71 for the past year, representing a decrease of 231.42% compared to the previous year. However, the EPS for the third quarter of the year improved to -$0.21, showing an increase of 33.87% compared to the previous quarter.
Overall, the financial performance of SILO stock on February 28, 2024, showed mixed results. Investors may want to closely monitor the company’s financial performance in the coming quarters to assess its long-term growth potential.
